1. Home
  2. FABC vs PHIO Comparison

FABC vs PHIO Comparison

Compare FABC & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fabric.AI Inc. Common Stock

FABC

Fabric.AI Inc. Common Stock

HOLD

Current Price

$2.00

Market Cap

15.0M

ML Signal

HOLD

Logo Phio Pharmaceuticals Corp.

PHIO

Phio Pharmaceuticals Corp.

HOLD

Current Price

$0.87

Market Cap

12.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FABC
PHIO
Founded
1997
2003
Country
United States
United States
Employees
108
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.0M
12.9M
IPO Year
1999
2011

Fundamental Metrics

Financial Performance
Metric
FABC
PHIO
Price
$2.00
$0.87
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 93.8K
88.9K
Earning Date
11-13-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $4,579,745.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$2.02
$0.81
52 Week High
$4.57
$4.19

Technical Indicators

Market Signals
Indicator
FABC
PHIO
Relative Strength Index (RSI) 35.85 34.92
Support Level N/A $0.83
Resistance Level $2.49 $1.12
Average True Range (ATR) 0.16 0.05
MACD -0.01 -0.01
Stochastic Oscillator 0.00 19.19

Price Performance

Historical Comparison
FABC
PHIO

About FABC Fabric.AI Inc. Common Stock

Fabric.AI Inc is an infrastructure company building a suite of fabless semiconductor technologies to power AI factories - smart data centers optimized for producing intelligence at scale. The company's innovations include MicroLED-based optical interconnects and other system-critical technologies that enable faster, more efficient, and more scalable AI workloads. Its mission is to transform data centers into unified production systems for artificial intelligence.

About PHIO Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Share on Social Networks: